×

Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease

  • US 9,644,241 B2
  • Filed: 09/13/2012
  • Issued: 05/09/2017
  • Est. Priority Date: 09/13/2011
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating a patient that has pancreatic ductal adenocarcinoma (PDAC) comprising:

  • a) measuring by reverse-transcriptase polymerase chain reaction (RT-PCR) from a fine needle aspirate (FNA) pancreatic sample from the patient the level of expression of up to 11 different miRNAs that include at least miR-135b and at least 4 of the following diff pair miRNAs;

    miR148a, miR-130b, miR-196a, miR-24, miR-375, and miR-96, wherein at least one of the miRNAs is a biomarker miRNA and one is a comparative miRNA and miR-217 is not one of the miRNAs;

    b) determining a diff pair value for diff pairs;

    miR135b/miR-24, miR130b/miR-135b;

    miR-135b/miR-148a;

    miR-148a/miR-196a;

    miR-135b/miR-96;

    miR-375/miR-135b and optionally miR-130b/miR-24 and,c) analyzing the diff pair values using a computer performing linear discriminate analysis, wherein the linear discriminate identifies the patient as having PDAC; and

    d) treating the identified patient with chemotherapy, radiotherapy, surgery, or immunotherapy to treat the PDAC.

View all claims
  • 14 Assignments
Timeline View
Assignment View
    ×
    ×